KRAS and non-small cell lung carcinoma: FASN inhibitor TVB-2640 is in phase II clinical trials as monotherapy for non-small cell lung cancer with KRAS mutations (NSCLC, KRAS, NCT03808558), in combination with paclitaxel and trastuzumab for triple-negative breast cancer (NCT03179904), and in combination with the anti-angiogenic drug bevacizumab for high-grade astrocytoma (NCT03032484).